San Francisco-based Chai Discovery and Bristol Myers Squibb (NYSE: BMY) have announced a collaboration to apply Chai’s generative AI antibody discovery platform across BMS’s broader portfolio, with the stated goal of building an AI-powered, continuously learning discovery system at BMS. The deal covers antibody candidate identification across multiple undisclosed targets. Financial terms were not disclosed.
